Cassava ends simufilam Alzheimer’s programme after second Phase III failure

While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in TSC-related epilepsy.

Mar 27, 2025 - 06:00

Cassava ends simufilam Alzheimer’s programme after second Phase III failure

While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in TSC-related epilepsy.

Read the original article

Tags:

Previous Article

FDA fast tracks Sanofi’s mRNA vaccine for chlamydia

Character Biosciences gains $93m for precision eye disease therapies

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Sonnet BioTherapeutics secures US patent covering two drug candidates

Sonnet BioTherapeutics secures US patent covering two d...

Nov 9, 2024

Diffusion Pharma’s stockholders support merger with EIP Pharma

Diffusion Pharma’s stockholders support merger with EIP...

Aug 16, 2023

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis

J&J eyes FDA approval for injection-based Tremfya in ul...

Nov 23, 2024